• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    2/27/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email

    OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024

    More prescriptions filled through February 2025 than in Q4 2024

    Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025

    Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance

    Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT

    LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provides a corporate update.

    "2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first novel inhaled therapy available for the maintenance treatment of Chronic Obstructive Pulmonary Disease ("COPD") in over 20 years," said David Zaccardelli, Pharm. D., President and Chief Executive Officer. "We are very pleased to report the extremely strong start to the launch continues to build momentum with more prescriptions dispensed through February 2025 than in the entire fourth quarter of 2024.

    "More than 4,600 unique healthcare professionals ("HCPs") including approximately 55% of our Tier 1 HCPs have prescribed Ohtuvayre. Additionally, to date, more than 275 HCPs have prescribed Ohtuvayre to over 20 patients in their practice. Ohtuvayre is being prescribed for maintenance therapy across a broad COPD population including those receiving background single, dual and approximately 50% on triple therapy. These data strengthen our belief that ensifentrine's novel bronchodilator and non-steroidal anti-inflammatory activity will redefine the treatment paradigm for COPD.

    "Alongside our commercialization efforts, in the third quarter we initiated two Phase 2 clinical trials: a dose-ranging trial with glycopyrrolate, a long-acting muscarinic antagonist ("LAMA"), to support a nebulized fixed-dose combination of ensifentrine and glycopyrrolate for the maintenance treatment of COPD, and a study assessing the safety and efficacy of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis ("bronchiectasis"). We are pleased to report the glycopyrrolate dose-ranging trial was successfully completed and we plan to initiate a dose ranging Phase 2b trial with a fixed-dose combination of ensifentrine and glycopyrrolate in the second half of 2025.

    "In addition to our successful Ohtuvayre launch, our development partner in Greater China, Nuance Pharma, announced in February 2025 that Ohtuvayre was approved in Macau, the first approval outside of the US, for the maintenance treatment of COPD. In addition, Nuance Pharma has completed enrollment in its own pivotal Phase 3 trial in China to evaluate ensifentrine for the maintenance treatment of COPD and expects to report results in mid-2025.

    "In 2025, we will continue to build on the successful commercialization of Ohtuvayre in the US while progressing our Phase 2 programs. We are also initiating activities with regulatory authorities in the European Union and the UK for potential marketing authorization application submissions for Ohtuvayre."

    Program Updates and Key Milestones

    The Company's near-term milestones include:

    • In the second half of 2025, the Company plans to start a dose-ranging Phase 2b trial to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine with glycopyrrolate. The Company has successfully completed a Phase 2 dose-ranging trial with glycopyrrolate to support this program.
    • The Company continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine in patients with bronchiectasis.
    • In 2025, the Company plans to progress the regulatory activities for potential marketing authorization application submissions for Ohtuvayre for the maintenance treatment of COPD in the European Union and in the UK.
    • In mid-2025, the Company's development partner in Greater China, Nuance Pharma, is expected to report results from its pivotal Phase 3 trial evaluating ensifentrine for the maintenance treatment of COPD in China.

    Fourth Quarter and Recent Highlights

    • In October 2024, the Company gave four oral presentations and presented two posters on analyses from the ENHANCE studies at CHEST Annual Meeting 2024. These included subgroup data supporting improvements in lung function, symptoms and quality of life, as well as reductions in the rate of exacerbations, regardless of COPD severity (moderate or severe), smoking status (current or former) and chronic bronchitis (with or without). An analysis of Ohtuvayre's impact on reducing exacerbation rates and COPD-related healthcare resource utilization was also presented.
    • In November 2024, the 2025 GOLD report added Ohtuvayre to the COPD treatment algorithm.
    • Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA, supporting a fixed-dose combination program for the maintenance treatment of COPD via a nebulizer.
    • On January 1, 2025, Ohtuvayre's product specific J-code became effective.
    • In February 2025, the Company's development partner in Greater China, Nuance Pharma, announced Ohtuvayre has been approved in Macau for the maintenance treatment of COPD in adult patients. This is the first regulatory approval outside of the US.

    Fourth Quarter 2024 Financial Results

    • Cash position: Cash and cash equivalents at December 31, 2024, were $399.8 million (December 31, 2023: $271.8 million).
    • Product sales: Net sales of Ohtuvayre were $36.6 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 million). The Company received FDA approval on June 26, 2024 and the product was commercially available beginning in August 2024.
    • Cost of sales: Cost of sales was $2.0 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 million), which included Ohtuvayre manufacturing costs incurred after US approval, inventory overhead costs and sales-based royalties.
    • R&D Expenses: Research and development ("R&D") expenses were $7.9 million for the fourth quarter ended December 31, 2024 (Q4 2023: $4.1 million). This increase of $3.8 million was primarily due to an increase of $3.2 million in clinical trial and other development costs as we initiated two Phase 2 studies in the third quarter of 2024 related to the combination of nebulized ensifentrine and glycopyrrolate and for Ohtuvayre in patients with bronchiectasis, and an increase of $1.1 million in share-based compensation.
    • SG&A Expenses: Selling general and administrative expenses ("SG&A") were $45.1 million for the fourth quarter ended December 31, 2024 (Q4 2023: $15.0 million). The increase of $30.1 million was driven primarily by an increase of $9.8 million in marketing and other commercial related activities, including travel, primarily related to the launch of Ohtuvayre, and an increase of $2.6 million in professional and consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization. Additionally, we had an increase of $8.8 million in people-related costs as we built out our commercial organization including much of the field sales team as well as an increase of $7.8 million related to share-based compensation.
    • Net loss: Net loss was $33.8 million for the fourth quarter ended December 31, 2024 (Q4 2023: Net loss $14.1 million).

    Full Year 2024 Financial Results

    • Product sales: Net sales were $42.3 million for the year ended December 31, 2024 (2023: $0 million) related to product sales of Ohtuvayre.
    • Cost of sales: Cost of sales was $2.6 million for the year ended December 31, 2024 (2023: $0 million), which included Ohtuvayre manufacturing costs incurred after US approval, inventory overhead costs and sales-based royalties.
    • R&D Expenses: R&D expenses were $44.6 million for the year ended December 31, 2024 (full year 2023: $17.2 million), an increase of $27.4 million. This increase was primarily due to an increase of $17.5 million in clinical trial and other development costs we incurred related to the two Phase 2 studies which were initiated in the third quarter of 2024 related to the combination of nebulized ensifentrine and glycopyrrolate and for Ohtuvayre in patients with bronchiectasis, the $6.3 million approval milestone, $3.1 million increase in share-based compensation, $2.0 million increase for people-related costs and $1.1 million related to pre-launch manufacturing costs for commercial supply. This was partially offset by a decrease of $1.3 million in consultant and professional fee costs which were higher in the prior year due to service costs associated with our New Drug Application and the related approval process.
    • SG&A Expenses: SG&A expenses were $149.8 million for the year ended December 31, 2024 (full year 2023: $50.4 million), an increase of $99.4 million. This increase was driven primarily by an increase of $29.7 million in marketing and other commercial related activities, including travel, primarily related to the launch of Ohtuvayre, a charge of $15.0 million for the first sale milestone and an increase of $7.3 million in professional and consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization. Additionally, we had an increase of $26.8 million in people-related costs as we built out our commercial organization including much of the field sales team as well as an increase of $18.8 million related to share-based compensation.
    • Net loss: Net loss was $173.4 million for the year ended December 31, 2024 (full year 2023: $54.4 million).

    Conference Call and Webcast Information

    Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 27, 2025, to discuss the fourth quarter and full year 2024 financial results and the corporate update.

    To participate, please dial one of the following numbers and ask to join the Verona Pharma call:

    • +1-800-836-8184 for callers in the United States
    • +1-646-357-8785 for international callers

    A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the fourth quarter and full year 2024 results press release will also be made available today on the Company's website.

    Important Safety Information

    Indication

    Ohtuvayre is a prescription medicine used to treat COPD in adults. COPD is a chronic (long-term) lung disease that includes chronic bronchitis, emphysema, or both.

    What is the most important information I should know about Ohtuvayre?

    Ohtuvayre can cause serious side effects, including:

    • Sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using Ohtuvayre and call your healthcare provider right away or go to the nearest hospital emergency room right away.
    • Mental health problems including suicidal thoughts and behavior. You may experience mood or behavior changes when taking Ohtuvayre. Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety, new or worse depression, acting on dangerous impulses, and/or other unusual changes in your behavior or mood.

    Do not use Ohtuvayre to treat sudden breathing problems. Always have a rescue inhaler with you.

    Who Should Not use Ohtuvayre?

    Do not use Ohtuvayre if you have had an allergic reaction to ensifentrine or any of the ingredients in Ohtuvayre.

    What should I tell my healthcare provider before using Ohtuvayre?

    Before you use Ohtuvayre, tell your healthcare professional if you have or have had a history of mental health problems including depression and suicidal behavior; have liver problems; are pregnant or plan to become pregnant; are breastfeeding. It is not known if Ohtuvayre may harm your unborn baby. It is not known if the medicine in Ohtuvayre passes into your breast milk and if it can harm your baby.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    What are the most common side effects of Ohtuvayre?

    The most common side effects of Ohtuvayre include back pain, high blood pressure, bladder infection and diarrhea.

    These are not all the possible side effects of Ohtuvayre. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    This summary does not include all the information about Ohtuvayre and is not meant to take the place of a discussion with your healthcare provider about your treatment.

    For further information, please see the full Prescribing Information, including the Patient Information Leaflet.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    For further information please contact:

    Verona Pharma plcTel: +1-844-341-9901
    Victoria Stewart, Senior Director of Investor Relations and Communications[email protected]
    Argot Partners

    US Investor Enquiries
    Tel: +1-212-600-1902

    [email protected]
    Ten Bridge Communications

    International / US Media Enquiries
    Tel: +1-781-316-4424

    [email protected]
    Wendy Ryan 



    About Verona Pharma

    Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as "anticipate," "believe," "plan," "expect," "intend," "may," "potential," "prepare," "possible" and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre to treat adult patients in the US with COPD, statements regarding our two recently initiated Phase 2 clinical trials, the Company's plans to initiate a Phase 2b clinical trial, potential regulatory approvals in the EU and UK, and Nuance Pharma's results from its pivotal Phase 3 trial, and the timing of any of the foregoing.

    These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: risks related to our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications, alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major pharmaceutical markets; our commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure, may not be adequate to successfully commercialize Ohtuvayre; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable; lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our profitability, and audits by tax authorities that could result in additional tax payments for prior periods; the terms of our credit agreement and the revenue interest purchase and sale agreement ("RIPSA") place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the RIPSA, our results of operations and financial condition may be harmed; our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics; and the other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 27, 2025, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Verona Pharma plc

    Consolidated Financial Summary

    (unaudited)

    (in thousands, except share and per share amounts)

     Three months ended December 31, Years ended December 31,
      2024   2023   2024   2023 
    Revenue       
    Product sales, net$36,637  $—  $42,261  $— 
    Other revenue 18   —   18   — 
    Total Revenue, net 36,655   —   42,279   — 
    Operating expenses       
    Cost of sales 2,039   —   2,582   — 
    Research and development 7,870   4,122   44,574     17,216 
    Selling, general and administrative 45,085   14,972   149,750   50,353 
    Total operating expenses 54,994   19,094   196,906   67,569 
    Operating loss (18,339)  (19,094)  (154,627)  (67,569)
    Other income/(expense)       
    Research & development tax credit 556   1,034   3,600   1,104 
    Loss on extinguishment of debt —   —   (3,653)  — 
    Interest income 3,994   3,292   15,262   12,761 
    Interest expense (10,317)  (623)  (23,542)  (2,057)
    Foreign exchange gain/(loss) (1,450)  1,206   (169)  1,866 
    Total other income/(expense), net (7,217)  4,909   (8,502)  13,674 
    Loss before income taxes (25,556)  (14,185)  (163,129)  (53,895)
    Income tax benefit/(expense) (8,271)  53   (10,289)  (474)
    Net loss$(33,827) $(14,132) $(173,418) $(54,369)
            
    Weighted average shares outstanding – basic and diluted 663,263,855   642,139,211   652,310,582   634,142,660 
            
    Loss per ordinary share - basic and diluted$(0.05) $(0.02) $(0.27) $(0.09)
            
      2024   2023     
    Cash and cash equivalents$399,757  $271,772     
    Total assets 474,242   308,124     
    Shareholders' equity$204,559  $249,283     
            


    Primary Logo

    Get the next $VRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    8/26/2022$31.00Overweight
    Piper Sandler
    11/12/2021$18.00 → $23.00Buy
    Canaccord Genuity
    More analyst ratings

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verona Pharma Announces June 2025 Investor Conference Participation

      LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please

      5/21/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

      Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

      5/6/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Financials

    Live finance-specific insights

    See more
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00

      4/21/25 8:39:43 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Verona Pharma with a new price target

      ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00

      1/10/25 8:44:57 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/18/24 4:20:05 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:57:21 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:56:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:31:56 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hahn Mark W sold $3,733,944 worth of Ordinary Shares (400,000 units at $9.33), decreasing direct ownership by 3% to 12,678,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:16:57 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zaccardelli David sold $3,734,579 worth of Ordinary Shares (400,000 units at $9.34), decreasing direct ownership by 3% to 13,590,168 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:15:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $0.50 and sold $1,502,928 worth of Ordinary Shares (160,000 units at $9.39) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/22/25 4:06:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    SEC Filings

    See more
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:33:47 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:31:13 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/20/25 4:30:55 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

      ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

      4/29/21 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care